$GH News

Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Guardant Health: Screening And MRD Are Just Getting Started

Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193

Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195

Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185

Stifel Maintains Buy on Guardant Health, Raises Price Target to $180

RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200

Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $200

JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $195

TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $210

BTIG Maintains Buy on Guardant Health, Raises Price Target to $195

Guardant Health, Inc. 2026 Q2 - Results - Earnings Call Presentation

Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook

Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript

Guardant Health Files Shelf Prospectus For Offering; Size Not Disclosed

Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est

Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate

Guardant Health: An Expensive Price For A Great Company

Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $190

Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $205